Li et al. [85] knocked down both A2AR and A2BR in CAR T cells via CRISPR and demonstrated strong antitumor efficacy in vitro and a further heightened efficacy in vivo in two patient derived (pancreatic cancer) xenograft models resulting in a low tumor load. This evidence concerns the gene ADORA2A and neoplasm.